publication date: Jun. 2, 2017

Conversation with The Cancer Letter Cary Gross: We need to learn to analyze real-world evidence rigorously

Cary Gross

Professor of medicine and of epidemiology, Yale School of Medicine



Cary Gross, professor of medicine and of epidemiology at Yale School of Medicine, has been working with a dataset of 35,000 non-small cell lung cancer patients, looking for signs of disparities in access to PD-1 checkpoint inhibitors.

Working with data gathered by Flatiron Health, Gross has also been pondering the role real-world evidence can legitimately play in the development and approval of cancer drugs.

The Flatiron dataset tracks the rapid uptake of immunotherapy agents over two years—illustrating, in real-time, more than a sevenfold increase from May 2015 through April 2017.

“Now that we know standard of cancer care can change so rapidly, the pressure is really on clinical community and policymakers to ensure that we are rapidly and rigorously assessing the impact of these new agents outside the trial setting,” Gross said to The Cancer Letter. He will be presenting the initial results of the study at the 2017 annual meeting of the American Society of Clinical Oncology in Chicago.

Continue reading Cary Gross: We need to learn to analyze real-world evidence rigorously

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.